Isoflavones benefit polycystic ovary syndrome patients
Polycystic ovary syndrome (PCOS), a common endocrine disorder among women of reproductive age, is mainly associated with hyperinsulinemia, impaired glucose metabolism, hyperandrogenism, and dyslipidemia. Moreover, emerging evidence has shown that elevated levels of inflammatory factors and biomarkers of oxidative stress in the blood and histological samples of women with PCOS might play important roles in the pathogenesis of PCOS. These disorders can increase the risk of type 2 diabetes mellitus, coronary heart disease, endometrial cancer and ovulatory dysfunction. New clinical data from Iran suggest PCOS patients benefit from soybean isoflavones.
This randomized, double-blind, placebo-controlled trial involved 70 women diagnosed with PCOS who were randomly allocated into two groups to take either 50 mg/d soy isoflavones or placebo for 12 weeks. Metabolic, endocrine, inflammation, and oxidative stress biomarkers were quantified at the beginning of the study and after the 12-week intervention.
Compared to the placebo group, soy isoflavone administration significantly decreased circulating serum levels of insulin and reduced insulin resistance. In addition, supplementation with soy isoflavones resulted in significant reductions in the free androgen index and serum triglycerides compared to the placebo group. There was also a significant increase in plasma total glutathione and a significant decrease in malondialdehyde levels by soy isoflavone intake compared with the placebo group.
Jamilian, M. and Asemi, Z. The effects of soy isoflavones on metabolic status of patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2016, 101, 3386-94.